SCHEMBL826095

SCHEMBL826095

FC(F)(F)c1cccc2[nH]ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.52
AHR P35869 2/20 0.50
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KIF11 P52732 1/20 0.47
TRPV1 Q8NER1 1/20 0.44
PIK3CD O00329 1/20 0.42
TRPA1 O75762 2/20 0.40
RHEB Q15382 4/20 0.40
CTNNB1 P35222 1/20 0.40
WNT3A P56704 1/20 0.40
MAPK1 P28482 1/20 0.40
ADRB1 P08588 1/20 0.40
HTR6 P50406 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39
PARP1 P09874 1/20 0.39
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
CA1 P00915 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225674 1.00 AXL (0.52) AXLAHRHSD17B10KDM4ESMN1; SMN2
SCHEMBL5720513 0.81 AHR (0.57) AHRPIK3CDTRPA1RHEBMAPK1
SCHEMBL2607555 0.79 AHR (0.50) AHRKIF11PIK3CDTRPA1RHEB
SCHEMBL5720599 0.79 AHR (0.50) AHRHSD17B10KDM4ESMN1; SMN2PIK3CD
SCHEMBL27515441 0.78 AHR (0.42) AXLAHRHSD17B10KDM4ESMN1; SMN2
SCHEMBL23051024 0.76 AHR (0.47) AHRKIF11PIK3CDTRPA1RHEB
SCHEMBL27437897 0.76 AHR (0.47) AHRKIF11PIK3CDRHEBMAPK1
SCHEMBL30720217 0.76 AHR (0.47) AHRKIF11PIK3CDRHEBMAPK1
SCHEMBL1536662 0.75 KDM4E (0.57) HSD17B10KDM4ESMN1; SMN2PARP1
SCHEMBL10264079 0.75 AHR (0.46) AHRKDM4EKIF11PIK3CDRHEB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616193-B2 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility SPERMATECH AS (NO) 2026-05-05 US disclosed
EP-3596089-B1 ANTIBACTERIAL COMPOUNDS UNIV NOTTINGHAM (GB) 2023-12-06 EP disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 US disclosed
CN-115768260-A 5- (1H-indol-3-yl) -oxazole, -oxadiazole and-furan derivatives as sperm motility enhancers 精液技术股份有限公司 2023-03-07 CN disclosed
US-20230066771-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC (US) 2023-03-02 US disclosed
CN-112479969-B 1, 3-di (1H-indole) group-1-fluorine-1-propylene derivative and synthetic method thereof 华南理工大学 2022-06-14 CN disclosed
US-11192888-B2 Antibacterial compounds THE UNIVERSITY OF NOTTINGHAM (GB) 2021-12-07 US disclosed
CN-108530335-B Indole compound and preparation method and application thereof 华南农业大学 2021-08-31 CN disclosed
US-20210130293-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC (US) 2021-05-06 US disclosed
CN-112479969-A 1, 3-di (1H-indole) group-1-fluorine-1-propylene derivative and synthetic method thereof 华南理工大学 2021-03-12 CN disclosed
US-20080139631-A1 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators SMITHKLINE BEECHAM CORPORATION (US) 2008-06-12 US disclosed
WO-2008060998-A1 INDOLE SULFONAMIDES AS SFRP-1 MODULATORS WYETH (US) 2008-05-22 WO disclosed
WO-2008060998-A1 INDOLE SULFONAMIDES AS SFRP-1 MODULATORS WYETH (US) 2008-05-22 WO disclosed
WO-2008042571-A2 SUBSTITUTED INDOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-04-10 WO disclosed
EP-1848694-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F. Hoffmann-Roche AG (CH) 2007-10-31 EP disclosed
WO-2006082001-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F.HOFFMANN-LA ROCHE AG (CH) 2006-08-10 WO disclosed
WO-2006082001-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F.HOFFMANN-LA ROCHE AG (CH) 2006-08-10 WO disclosed
US-20060178381-A1 Heterocyclic-substituted phenyl methanones HOFFMANN-LA ROCHE INC. 2006-08-10 US disclosed
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2005-07-07 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192888-B2 Antibacterial compounds CFTR, CLPP, MRPL21 AXL 2946/4885AHR 2046/4885HSD17B10 1404/4885
US-20060178381-A1 Heterocyclic-substituted phenyl methanones CYP2B6, CYP2D6, CYP1A2 AXL 2644/4885AHR 56/4885HSD17B10 109/4885
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst PIN4, IPO5, HLCS AXL 621/4885AHR 67/4885HSD17B10 2772/4885
US-12616193-B2 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility NR5A1, CATSPER1, HCN3 AXL 3109/4885AHR 456/4885HSD17B10 477/4885
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 AXL 2237/4885AHR 280/4885HSD17B10 279/4885
US-20080139631-A1 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators AR, NR5A1, NR3C2 AXL 1167/4885AHR 68/4885HSD17B10 291/4885
US-20210130293-A1 NUCLEAR RECEPTOR MODULATORS NR1I2, NR1H2, NR5A2 AXL 2169/4885AHR 200/4885HSD17B10 577/4885
US-20230066771-A1 NUCLEAR RECEPTOR MODULATORS NR1I2, NR1H2, NR5A2 AXL 2169/4885AHR 200/4885HSD17B10 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.